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Objectives This study sought to evaluate long-term outcomes of carotid stenting (CAS) versus carotid endarterectomy (CEA)
based on physician-guided indications.
Background The issue regarding long-term outcome of CAS versus CEA in patients with carotid stenosis is clinically relevant
but remains unsettled.
Methods Consecutive patients (71% men, mean age 71.3 years) treated by CEA (n  1,118) or CAS (n  1,084) after a
training phase were reviewed. Selection of treatment was based on better-suitability characteristics (morphology
and clinical). Data were adjusted with propensity score analysis and stratified by symptoms, age, and sex.
Results Thirty-day stroke/death rates were similar: 2.8% in CAS and 2.0% in CEA (p  0.27). The risk was higher in
symptomatic (3.5%) versus asymptomatic (2.0%) patients (p  0.04) but without significant difference between
CAS and CEA groups. Five-year survival rates were 82.0% in CAS and 87.7% in CEA (p  0.05). Kaplan-Meier
estimates of the composite of any periprocedural stroke/death and ipsilateral stroke at 5 years after the proce-
dure were similar in all patients (4.7% vs. 3.7%; p  0.4) and the subgroups of symptomatic (8.7% vs. 4.9%;
p  0.7) and asymptomatic (2.5% vs. 3.3%; p  0.2) patients in CEA versus CAS, respectively. Cox analysis, ad-
justed by propensity score, identified statin treatment (p  0.016) and symptomatic disease (p  0.003) associ-
ated with the composite end point. There were no sex- or age-related significant outcome differences.
Conclusions When physicians use their clinical judgment to select the appropriate technique for carotid revascularization CAS
can offer efficacy and durability comparable to CEA with benefits persisting at 5 years. (J Am Coll Cardiol
2011;57:664–71) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.09.041Durable stroke prevention is the objective of treatment of
carotid stenosis. Although several randomized controlled
trials (RCTs) have addressed the issue of outcomes of
carotid stenting (CAS) versus carotid endarterectomy
(CEA) (1–4), many of these trials suffered from lack of
interventional operator experience or inconsistent use of
embolic protection devices and the quality of CAS proce-
dures was low (2–4). Furthermore, in all RCTs, the results
were available at 4 years after CAS/CEA, and the
information on CAS is now affected by the lack of substan-
tial data on delayed outcomes. The question on what is the
long-term outcome of CAS compared with CEA in pa-
tients with a carotid stenosis is clinically relevant and
remains unsettled. The purpose of this study was to compare
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2010, accepted September 16, 2010.the 5-year safety of CEA with CAS performed with cerebral
protection and current techniques in a large population outside
RCTs by using physician-guided assignment of treatment.
Methods
Patients entered into a prospectively compiled computerized
database of all primary extracranial carotid revasculariza-
tions (CAS and CEA) performed at a single vascular
surgical center from January 2001 to March 2009 were
analyzed. All patients with either 60% symptomatic or
70% asymptomatic carotid stenosis were treated by sur-
geons. For the purpose of the study, patients who received
revascularization for recurrent carotid stenosis and bypass
grafts were excluded. All procedures were performed after
the training phase. The revascularization treatment choice
(CAS/CEA) was left to the discretion of the treating
surgeon according to better suitability and periprocedural
risk evaluation as well as plaque and vessel morphology and
presence of comorbidities. This assignment strategy was
used in other nonrandomized studies (5). Usually, patients
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vascular disease precluding femoral access, or extremely
tortuous carotid anatomy were excluded from CAS. Simi-
larly, known allergies to aspirin, clopidogrel, or contrast
media and renal insufficiency were considered exclusion
criteria for CAS. High-neck carotid bifurcation and long
carotid lesions as well as obesity and ongoing dual antiplate-
let therapy were relative contraindications for CEA.
In our center, the caseload necessary to perform safe CAS
(assuming 2% as the safety threshold per year for major
periprocedural complication rate) included the first 195
procedures. It was after this training that the rate of
disabling strokes (mainly occurring during the catheteriza-
tion and filter time frames of CAS) significantly decreased
and remained stable at 2% per year in each of the
following years (6). To avoid bias due to the learning curve
effect of the operators, the first 195 CAS performed within
the training phase (2001 to 2003 interval) were excluded
from this study. With increasing experience and by applying
the best suitability morphology and clinical criteria learned
during the training, the number of CAS by year expanded to
reach and overcome the numbers of CEA. In the more
recent years, CEA was selected for fewer and usually the
most complex cases (e.g., acute symptoms, unstable plaque).
Therefore, CEAs performed in the last 2 years of the study
(2008 and 2009, when these high-risk selection criteria were
used) were excluded from the present analysis to avoid
possible major selection bias. Of carotid revascularization
procedures performed by year for primary carotid stenosis,
50% in 2004, 50.5% in 2005, 19.5% in 2006, and 19.7% in
2007 were performed by CEA.
CAS procedure. All patients received aspirin (100 to 325
mg once daily) and clopidogrel (75 mg once daily) or
ticlopidine (250 mg twice daily) before the procedure.
Carotid stenting was carried out following a standardized
protocol in an endovascular room equipped with a high-
quality fixed-imaging system (Axiom Artis FA, Siemens,
Berlin, Germany).
Minimal or no sedation was used during the procedure
and neurological status was continuously monitored. Intra-
venous heparin (100 U/kg) was routinely given before
selective catheterization of the common carotid artery and
not reversed at the end of the procedure. Percutaneous
transfemoral or transbrachial approaches under local anes-
thesia were used to allow selective engagement of the target
carotid artery. Variable models of cerebral protection devices
and carotid stents (open cell, close cell, or hybrid configu-
ration; tapered or straight) were employed in all procedures.
The choice of specific material depended on vessel anatomy
and lesion characteristics. Close cell stents were generally
used in straight vessels and in the presence of soft plaque.
There was a higher preference for using a filter as cerebral
protection; in selected cases (carotid tortuosity, extremely
soft plaque profile at ultrasound, and so on), crossing a
lesion with a filter was avoided by using a proximalocclusion system. The reference
vessel diameter was determined
(stent size/length choice) accord-
ing to pre-operative ultrasound
measurements. In the case of a
large discrepancy between com-
mon carotid and internal carotid
artery diameters, a tapered stent
was deployed. After stent de-
ployment, completion angiogra-
phy was performed. Closure de-
vices for the access control were
used since 2006.
Post-procedure antiplatelet therapy included dual drug
treatment (aspirin and thienopyridines) for a minimum of 1
month and continued at the treating physicians’ discretion.
CEA procedures. Carotid endarterectomy was performed
under local or general anesthesia. All patients were under
antiplatelet 1-drug therapy, either aspirin (100 to 325 mg
once daily) or ticlopidine (250 mg twice daily) or thien-
opyridine (clopidogrel 75 mg daily). Shunts were used
selectively according to clamping intolerance. Eversion or
patch and occasionally direct primary closure were used as
arterial closure techniques. Patient monitoring followed the
same modality as CAS in awake patients; stump pressure
measurements were used when general anesthesia was em-
ployed. Systemic heparinization was used at the same
dosage as CAS and then reversed after carotid declamping.
Patient evaluation/definitions. With coronary artery dis-
ease, we included patients with documented history of
angina or myocardial infarction, regardless of duration and
type of treatment received. Patients with peripheral artery
disease were considered those with documented lower limb
intermittent claudication or critical limb ischemia. Features
and time of pre-operative symptoms were evaluated by
external neurological audit. Patients were defined as symp-
tomatic when ipsilateral hemispheric or retinal symptoms
occurred within 6 months from the procedure. Stroke was
defined as any new hemispheric or retinal neurological event
persisting 24 h and classified as fatal, disabling (modified
Rankin score 3), or nondisabling (modified Rankin score
3). Myocardial infarction was diagnosed by the cardiolo-
gist in the occurrence of persistent ST-segment changes
and/or new Q-wave in 2 leads or the presence of elevated
enzymes (including troponin 0.1 ng/ml).
The degree and characteristics of carotid stenosis at
baseline and during follow-up were assessed with duplex
ultrasound by experienced operators who defined site, de-
gree, length of stenosis, plaque characteristics, and vessel
measurements previously validated against angiography as a
gold standard technique. “Complex carotid plaque” was
judged by ultrasound when lack of uniform pattern and
prevalence of soft appearance was evident. Data were
confirmed by grossly intraoperative assessment during
CEA. Degree of stenosis was defined according to the
Abbreviations
and Acronyms
CAS  carotid stenting
CEA  carotid
endarterectomy
MI  myocardial infarction
RCT  randomized
controlled trial
TIA  transient ischemic
attackUniversity of Washington modified duplex velocity criteria
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formed selectively, in cases of uncertainty at ultrasound
examination. Degree of stenosis was always confirmed by
visual evaluation with angiography during CAS.
Cerebral computed tomography scan was used in symp-
tomatic patients to assess the extent of recent lesions if any.
Patients scheduled for CAS or CEA with antiplatelet
intolerance or under anticoagulation for coexisting medical
comorbidities continued to receive their baseline therapy.
Written consent was obtained from all patients before
revascularization.
Outcome measures. Primary end point was the combined
isk of any stroke or death within 30 days (perioperative)
nd any ipsilateral stroke after the procedure. Secondary end
oints were stroke, death, transient ischemic attack (TIA),
yocardial infarction (MI), and local complications (hema-
oma, cranial nerve injuries) occurring within 30 days and
he rate of stroke, death, and restenosis after the procedure.
ollow-up. Outpatient clinical and ultrasound examina-
ions were scheduled at regular intervals (at 6 and 12 months
nd yearly thereafter) and symptom status was assessed.
arotid restenosis was set at50% using ultrasound criteria
7). Repeat computed tomography angiography or angiog-
aphy was performed only if repeat revascularization was
eing considered. Patients were instructed to report any new
eurological symptoms occurring after hospital discharge.
n cases of neurological symptoms or uncertainty occurring
nytime after the procedure, the patients were evaluated by
certified independent neurologist expert in vascular
isease.
tatistical analysis. Analysis of data was by treatment
actually received. Data are shown as frequencies and per-
centages for categorical variables and mean (SD) for
continuous variables. Characteristics of patients in CAS and
CEA groups were compared using chi-square and Fisher
exact tests (when appropriate) for categorical variables, and
analysis of variance or Student t test for continuous vari-
Baseline Characteristics in CEA and CAS PopulTable 1 Baseline Characteristics in CEA an
CEA (n  1,11
Age, yrs 71.06 7.7
Women 326 (29.1)
Hypertension 889 (79.5)
Diabetes 298 (26.6)
Peripheral artery disease* 241 (21.6)
On statins† 361 (33.6)
Hyperlipidemia 581 (51.9)
Coronary disease 298 (26.6)
Complex plaque 469 (41.9)
Atrial fibrillation 35 (3.1)
Contralateral occlusion 81 (7.2)
Symptomatic disease 416 (37.2)
Bilateral procedure‡ 84 (7.5)
Values are mean  SD or n (%). *Patients with lower limb claudicat
received staged CAS or staged CEA on both carotid sides for both left and rig
CAS  carotid stenting; CEA  carotid endarterectomy.bles. Unadjusted and adjusted odds ratios (ORs) with
orresponding 95% confidence intervals (CIs) were used to
ompare outcomes between CAS and CEA.
Analyses of perioperative and late outcomes were strati-
ed by pre-operative symptoms to account for evident
ifferences in symptomatic and asymptomatic distribution
f patients.
The rates of end points at 5 years were estimated with
aplan-Meier method to compensate for patient dropouts
nd the level of significance was calculated with log-rank
est and its standard error (SE). Curves were displayed up to
value of SE 0.10. Symptomatic and asymptomatic
atients were analyzed separately.
Because surgery or endovascular treatment was not ran-
omly assigned in this population, potential confounding
nd selection biases were addressed by analyzing the rate of
he composite outcome (any stroke or death within 30 days
nd any ipsilateral stroke after procedure) with multivariate
nalyses after using backward elimination methods. The
ollowing variables were included in the model: treatment
carotid stenting), age, sex, pre-operative symptoms, con-
ralateral occlusion, coronary disease, peripheral artery dis-
ase, diabetes, hypertension, statin therapy, and complex
laque. Interactions among the 11 covariates and composite
utcome were assessed with Cox regression analysis.
To address the differences between CAS and non-CAS
atients in a nonrandomized study, a propensity score was
lso derived, reflecting the probability that a patient would
ndergo CAS. This was accomplished by multivariable
ogistic regression models using CAS as the dependent
utcome variable and entering all measured baseline patients
haracteristics shown in Table 1 (except for bilateral proce-
ure and atrial fibrillation) as covariates (8,9). The score was
sed in trying to adjust the estimates of the main composite
utcome using 3 approaches with Cox regression models:
nadjusted, adjusted for raw propensity score, and adjusted
s Populations
CAS (n  1,084) p Value
71.54 7.50 0.13
314 (28.9) 0.925
907 (83.7) 0.013
333 (30.7) 0.038
149 (13.7) 0.001
465 (42.9) 0.001
672 (61.9) 0.001
398 (36.7) 0.001
339 (31.3) 0.001
38 (3.5) 0.55
82 (7.6) 0.807
268 (24.7) 0.001
77 (7.1) 0.70
ata available for 1,074 CEA and 1,084 CAS patients. ‡Patients whoationd CAS
8)
0
ion. †D
ht carotid stenosis.
t
p
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variate models using stepwise selection method (9).
Subgroup analyses in models stratified by symptoms, sex,
and age were performed to balance for potential subgroup
discrepancies in CAS versus CEA. For age categories, we
used the age cutoff applied in the CREST (Carotid Revas-
cularization Endarterectomy Versus Stenting Trial) (69
years vs. 70 years; 80 years).
A value of p 0.05 was considered statistically significant
for all measurements. Stat-Calc-EPIINFO 6.0 (PC version
3.5.1, Centers for Disease Control and Prevention [CDC]
Atlanta, Georgia) and SPSS (PC version 13.00 Win pack-
age, SPSS, Inc., Chicago, Illinois) were used for all data
analyses.
Results
Over the study period, 2,202 interventions for primary
carotid stenosis were performed in 2,041 patients: 1,084
CAS (in 1,007 patients) and 1,118 CEA (in 1,034 patients).
There were 1,562 men and 640 women; mean age was 71.3
years (range 46 to 92 years).
Demographic and baseline characteristics for CAS and
CEA populations are displayed in Table 1.
The CAS patients were less likely to have a history of
peripheral artery disease or symptomatic disease and more
likely to have hypertension, coronary disease, diabetes, and
be on statin treatment for hyperlipidemia (Table 1). Com-
plex carotid plaque, as judged by ultrasound, was more
frequently detected in CEA (41.9% vs. 31.2%, p  0.001).
Periprocedural outcomes. Carotid stenting was originally
planned in 2,004 procedures. In 20, the procedure was not
accomplished because it was not possible to approach or
cross the carotid lesion for the following reasons: difficulty
in cannulation of bovine arch (n  2), extreme vessel
ortuosity (n  10), pre-occlusive lesions (n  6), or both
re-occlusive lesion and tortuosity (n  2). These patients
Periprocedural (Within 30 Days) Outcomes in CTable 2 Periprocedural (Within 30 Days) Ou
CAS
(n  1,084)
Acute stent removal/early thrombosis 4 (0.4)
Hospital stay, days 2.9 1.5
Stroke or death 31 (2.8)
Disabling stroke 12 (1.1)
Nondisabling stroke 19 (1.7)
Deaths —
Fatal stroke —
Nonfatal strokes 31 (2.8)
TIA 39 (3.6)
MI 3 (0.3)
MACE 34 (3.1)
Cranial nerve injury —
Access/neck hematoma 15 (1.4)
Values are n (%) or mean  SD, unless otherwise indicated.
CI  confidence interval; MACE  major adverse clinical events (any st
infarction; OR  odds ratio; TIA  transient ischemic attack; other abbreviatwere censored from CAS and analyzed according to the
treatment they actually received. The remaining 1,084
completed CAS procedures were all accounted for the CAS
group. In this group, 4 patients required stent removal for
acute complications after successful CAS. Three male pa-
tients (2 with both atrial fibrillation and anticoagulant
therapy) developed acute stent thromboses associated with
TIA immediately after an uneventful procedure. In a female
patient, repeated TIA occurred after stent deployment for
plaque protrusion through the stent struts. All the 4 patients
were uneventfully converted to CEA. There was no tech-
nical failure in the CEA group.
Periprocedural outcomes are listed in Tables 2 and 3.
The 30 day (periprocedural) risk of stroke or death in
overall CAS and CEA populations was 2.5% (54 of 2,202);
18 periprocedural strokes were disabling.
Periprocedural outcome measures in CAS compared with
CEA are reported in Table 2. There were no significant
differences in periprocedural risk of stroke or death between
CAS and CEA procedures: 2.8% (31 of 1,084) after CAS
versus 2.0% (23 of 1,118) after CEA; p  0.27 (Table 2).
There were no deaths in the CAS group. In the CEA
group, 3 fatal strokes and 3 cardiac deaths occurred. One
patient developed severe congestive heart failure and died 3
days after CEA performed for a recent stroke. Another
patient developed fatal MI after she was uneventfully
discharged. The third cardiac death occurred in a patient
who developed neck hematoma, MI, and pneumonia soon
after surgery and died on post-operative day 4.
Any perioperative major adverse events (including any
stroke, death, and any MI) occurred in 3.1% of CAS and
2.7% of CEA (p  0.61). The rates of periprocedural MI
were similarly distributed between CAS and CEA pa-
tients: 0.3% in CAS versus 0.4% in CEA (p  1.00).
Rates of TIA were higher in CAS (3.6%) than in CEA
(1.1%) patients, p  0.001, whereas cranial nerve injuries
d CAS Populationses in CEA and CAS Populations
CEA
(n  1,118) OR 95% CI p Value
— 0.001
4.34 2.3 0.001
23 (2.0) 1.4 0.81–2.42 0.27
6 (0.5) 2.0 0.77–5.55 0.21
14 (1.3) 1.4 0.71–2.78 0.42
6 (0.54) 0.03
3 (0.3) 0.25
17 (1.5) 1.9 1.05–3.43 0.04
12 (1.1) 3.4 1.80–6.53 0.001
4 (0.4) 0.7 0.19–3.09 1.00
30 (2.7) 1.2 0.71–1.92 0.61
38 (4.4) 0.001
18 (1.6) 0.9 0.43–1.68 0.70EA antcomroke, any death, and any myocardial infarctions); MI  myocardial
ions as in Table 1.
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p  0.001).
Among the combined CAS and CEA population (n 
2,202), the periprocedural stroke or death rate was lower in
asymptomatic patients, 2.0% (30 of 1,518), than in symp-
tomatic patients, 3.5% (24 of 684; p  0.04). Among
symptomatic patients (n  684), the rate was 4.5% in CAS
versus 2.9% in CEA, p  0.29; among asymptomatic
patients (n  1,518), the rate was 2.3% in CAS versus 1.6%
in CEA; p0.36 (Table 3).
Distribution of periprocedural stroke or death risk be-
tween CAS and CEA in women and in men and within the
69-, 70-, and 80-years age categories of patients are
shown in Table 3.
Late outcomes. Mean follow-up was 33.05  21.7
months. All the patients, with the exception of 59 unavail-
able, had a minimum of 6 months of follow-up. Follow-up
ranged from 6 to 108.4 months.
During the observation period, 178 patients died (n  74
in CAS, n  104 in CEA) and 12 cerebral hemorrhages (1
Figure 1 5-Year Kaplan-Meier Estimates of
Freedom From All-Cause Mortality
Five-year Kaplan-Meier estimates of freedom from all-cause mortality in carotid
stenting and carotid endarterectomy populations. CAS  carotid stenting; CEA
 carotid endarterectomy.
Periprocedural Stroke or Death Risk: Subgroup AnalysisTable 3 Periprocedural Stroke or Death Risk: Subgroup Analys
Subgroup Total CAS (n  1,084)
Symptomatic 684 12/268 (4.5)
Asymptomatic 1,518 19/816 (2.3)
Age 69 yrs 820 6/382 (1.6)
Age 70 yrs 1,382 25/702 (3.6)
Age 80 yrs 200 4/95 (4.2)
Women 640 7/314 (2.2)
Men 1,562 24/770 (3.1)
Values are n or n (%), unless otherwise indicated.
Abbreviations as in Tables 1 and 2.nonfatal) were recorded (n  5 after CAS, n  7 after
CEA). The 5-year survival rates from any cause mortality
were similar for CAS versus CEA (82.0% vs. 87.7%, p 
0.050) populations (Fig. 1).
The actuarial incidence of ipsilateral late stroke after the
procedure was 0.9% in CAS versus 2.7% in CEA. There
were no differences at 5 years after the procedure in
Kaplan-Meier estimates of the major composite end point
(combined risk of any stroke or death within 30 days and
any ipsilateral stroke after the procedure) between CAS
(3.7%) and CEA (4.7%) groups (p  0.4) (Fig. 2).
There were no significant differences between CAS and
CEA in Kaplan-Meier composite end point rates for any
subgroup (symptomatic, asymptomatic, women, men, older,
or younger patients) comparisons. Among symptomatic
patients, the rates were 4.9% in CAS versus 8.7% in CEA
(p  0.67); among asymptomatic patients, the rates were
3.3% in CAS versus 2.5% in CEA (p  0.2). Among
women, the rates were 4.2% in CAS versus 6.4% in CEA
(p  0.3); among men, the rates were 3.6% in CAS versus
Figure 2
5-Year Kaplan-Meier Estimates
of Freedom From Ipsilateral Stroke
Plus Any Periprocedural Stroke or Death
Five-year Kaplan-Meier estimates of freedom from ipsilateral stroke plus any
periprocedural stroke or death in carotid stenting and carotid endarterectomy
populations. Abbreviations as in Figure 1.
Periprocedural Stroke or Death
(n  1,118) OR 95% CI p Value
/416 (2.9) 1.6 0.69–3.57 0.29
/702 (1.6) 1.5 0.71–3.17 0.36
/438 (2.0) 0.8 0.27–2.16 0.80
/680 (2.0) 1.7 0.91–3.37 0.12
/105 (4.8) 0.9 0.23–3.12 1.00
/326 (3.1) 0.7 0.27–1.91 0.62
/792 (1.6) 1.9 0.97–3.81 0.07is
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among older patients (70 years) rates were 4.0% in CAS
and 5.4% in CEA (p  0.4); among younger patients (69
years) rates were 3.2% in CAS and 3.5% in CEA (p  0.9).
During follow-up, recurrent stenosis of 50% or more was
detected in 66 patients (28 CAS and 38 CEA) without
significant difference between CAS and CEA patients in
Kaplan-Meier estimates at 5 years: 3.4% versus 5.8% (p 
0.7) (Fig. 3). Only 6 recurrent stenoses (4 in CEA and 2 in
CAS) led to neurological symptoms.
Cox regression analysis after adjusting for 11 potential
confounders with backward elimination demonstrated that
symptomatic stenosis (hazard ratio [HR]: 2.15; 95% CI:
1.32 to 3.5; p  0.002) was the only significant positive
predictor of the composite end point (combined risk of any
stroke or death within 30 days and any ipsilateral stroke
after the procedure). The use of pre-operative statin was the
only negative predictor (HR: 0.46; 95% CI: 0.25 to 0.83;
p  0.01) associated with composite end point.
Propensity for CAS use. Patients had a higher propensity
to be receiving CAS with a history of coronary artery disease
(OR: 1.5; p  0.001), hypertension (OR: 1.2; p  0.041),
iabetes (OR: 1.2; p  0.018), hyperlipidemia (OR: 1.2,
 0.039), statin therapy (OR: 1.33, p  0.007), and
ncreasing age (OR: 1.33, p  0.007). Patients had a lower
ropensity to be receiving CAS with a history of neurolog-
cal symptoms (OR: 0.59, p  0.001), peripheral disease
OR: 0.49, p  0.001), and presence of complex plaque
OR: 0.61, p  0.001). After adjusting for the derived
ropensity score, the associations with the main outcome
emained essentially unchanged. Whether the propensity
core was allowed to be removed or was forced into the Cox
odel (either with or without other covariates) did not
nfluence the final prediction significantly. Carotid stenting
Figure 3 5-Year Probability of Restenosis After Procedure
Five-year probability of restenosis after the procedure in carotid stenting
and carotid endarterectomy populations. Abbreviations as in Figure 1.as not an independent predictor of the main compositeclinical end point in this analysis (HR: 1.4; 95% CI: 0.85 to
2.33; p  0.17). Statin was confirmed as a negative
independent predictor (HR: 0.49; 95% CI: 0.27 to 0.87;
p  0.016) and symptomatic carotid as a positive predictor
of the composite end point (HR: 2.0; 95% CI: 1.2 to 3.26;
p  0.003).
Discussion
Both CAS and CEA appear to have low perioperative
complications and excellent longer-term results and may be
considered useful tools for preventing stroke in patients with
carotid stenosis. In trained settings using modern technol-
ogy and appropriate physician-guided indications of best
suitability, catheter-based treatment with stent for carotid
stenosis can be successfully accomplished with low peripro-
cedural major complication (stroke/death rate: 2.8%) and
can provide durable resolution of carotid stenosis in 96.6%
of patients at 5 years of follow-up with low risk of late
ipsilateral stroke.
Our periprocedural and late data, based on physician-
guided and not on random assignment of treatment, are
similar to those recently shown by the CREST study, which
has been the most recent and largest RCT (over 2,500
patients enrolled), comparing CAS (n  1,262) and CEA
(n  1,240) in average risk patients, and is the only
randomized trial to include asymptomatic and symptomatic
patients and to require only well-trained operators for both
the procedures before randomization (1). Our results con-
firmed and estimated at 5 years the initial findings of the
CREST study (assessed at a median follow-up of about 2.5
years after treatment): the main composite end point (com-
bined risk of any stroke or death within 30 days and any
ipsilateral stroke after the procedure) rates were 3.7% in
CAS versus 4.7% in CEA (p  0.4). Nevertheless, our data
offer the opportunity to analyze outcomes in a large number
of consecutive patients treated for carotid stenosis with CAS
and CEA reflecting the modern “real-world” scenario out-
side the selected within-trial population.
In addition, this study provides data on direct comparison
between CAS and CEA in the longer-term showing that
the nonprocedural risk of stroke might be particularly low
after CAS: 0.9% at 5 years. This finding, in accordance with
other literature data (10–14), is important because some
observers had anticipated that an increased rate of late
stroke after CAS could be expected because of a most likely
higher probability of restenosis.
Although the aim of any treatment of carotid stenosis is
long-term prevention of stroke, the long-term rate of
neurological events after carotid angioplasty with stenting
(by using today’s technique) remains uncertain because little
data, and none from RCTs, on late clinical outcome after
CAS (14–17) are available. Although, without exception,
the EVA-3S (Endarterectomy Versus Angioplasty in Pa-
tients With Symptomatic Severe Carotid Stenosis) (11), the
SAPPHIRE (Stenting and Angioplasty with Protection in
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SPACE (Secondary Prevention With Antioxidants of Car-
diovascular Disease in End-Stage Renal Disease: Random-
ized Placebo-Controlled Trial) (10), and the CREST (1)
studies, each reported that following successful stenting
(i.e., assuming no strokes or deaths in the first 30 days) CAS
was as durable as CEA with high freedom from late stroke
rates, the length of follow-up in these studies was restricted
to a maximum of 4 years.
The SPACE trial (10) suggested that carotid restenosis
risk might be higher after endovascular treatment: life-table
estimates of restenosis up to 2 years were 10.7% in the
stenting versus 4.6% in the CEA groups (p  0.0009), even
hough only 2 restenoses were symptomatic. Conversely,
ur data showed that the risk of restenosis after CAS might
e slightly lower than after CEA: 3.4% versus 5.8% (p 
.7) at 5 years, respectively. Most restenoses after CAS
ccurred early, likely as a consequence of intimal hyperplasia
r healing process, and very few were associated with
ecurrence of symptoms. Nevertheless, criteria for stenosis
easurements, different thresholds, and ultrasound-
ubjective assessments make comparisons in restenosis rate
mong different studies unreliable (18,19). “Restenosis”
hould be regarded as a secondary, minor end point in
tudies evaluating stroke prevention.
It has been also suggested that in CAS patients the
pparent small long-term risks might be decompensated
y the higher periprocedural risk, defeating any benefit
rovided from revascularization. Patient selection is es-
ential to assign best-suited patients to the lower-risk
reatment. Periprocedural risk of nondisabling strokes
ight be higher during CAS and cardiac risk might be
igher during CEA (1), as our data in part confirmed.
he lack of randomization and the use of physician-
uided more than random assignment of treatment al-
owed in our population a larger prevalence of patients
ith cardiac disease in the CAS arm (36.7% vs. 26.6%;
 0.001). Yet, CAS patients compared with CEA
atients showed no increase (0.3% vs. 0.4%) in peripro-
edural cardiac events (MI), whereas all 3 cardiac deaths
ccurred in the CEA group, confirming CEA as a
rocedure with higher cardiac hazards. Our symptomatic
atients showed higher risks than asymptomatic patients
n either the periprocedural period or the long term. For
ymptomatic patients, the risk of periprocedural stroke
uring CAS was higher although there were no statisti-
ally significant differences in rates when compared with
EA patients (4.5% vs. 2.9%; p  0.29).
Our study failed to show any significant increase in early
nd late risks for CAS versus CEA in women or in older
atients. Nevertheless, like the CREST trial (1), a trend
oward increased periprocedural risk in 70-years patients
3.6% vs. 2.0%, p  1.05) and decreased risk in younger
atients (1.6% vs. 2.0%, p  0.8) was found.
Based on this study, patients with unfavorable aortic archnatomy, extreme tortuous carotid anatomy, or severe periph-eral vascular disease precluding femoral access, as well as
known allergies to aspirin or clopidogrel should be considered
preferentially for CEA. Patients with severe coronary disease,
high-neck carotid bifurcation, and obesity should be consid-
ered at increased risk during CEA and might be best suited for
CAS. The use of statin was the only variable to be indepen-
dently associated with improved long-term outcome.
Study limitations. Our data reflect practice in a dedicated
high-volume vascular center including large-volume endo-
vascular/vascular surgeons who benefit from the cooperation
and support of a team of interventionalists and neurologists.
Our findings might not be reproducible under less ideal
conditions (and may not reflect management of patients
treated at many community hospitals). Second, patients
were not randomized; this study rather reflects a retrospec-
tive observation and results may partially be related to
selection bias. Even after adjustment with the aid of
multivariate models, propensity score, and subgroup strati-
fications, the full clinical picture that determines outcomes
in surgery versus endovascular therapy may not be fully
balanced. Finally, as with all retrospective studies, the
database is subject to referral and ascertainment bias, in-
cluding patient reliability in accurately reporting new symp-
toms that could allow investigators to underestimate neu-
rological event rates assigned by independent neurologists in
both CAS and CEA groups.
Conclusions
Our results demonstrate that using clinical and morphology
criteria we were able to select CAS rather than CEA for
patients undergoing carotid revascularization without compro-
mising long-term vessel patency and stroke-free survival. The
periprocedural risks, similar to those of CEA, and durability of
symptom-free outcomes at 5 years support the efficacy of CAS
as a reasonable alternative to CEA in experienced centers.
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